Early detection revolution: pTau217 blood tests and AI diagnostics

Multiple pTau217 assays approved globally; Medicare coverage still blocked. AI models (Mayo, Mass General) show high accuracy. New two-cutoff approach reduces gray zone. Retinal imaging and sleep EEG emerging. Peripheral neuroinflammatory biomarkers (glial activation) are expanding the blood test landscape. Policy barriers and implementation challenges remain key issues.